Friday June 23rd 2017

Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury.

In this study we show that levels of APP, the enzymes cleaving APP (Bace1 and γ-secretase), and Aβ are significantly increased from 1 to 3 days after impact spinal cord injury (SCI) in mice. To determine the role of Aβ after SCI, we reduced or inhibited Aβ in vivo through pharmacological (using DAPT) or genetic (Bace1 knockout mice) approaches. We found that these interventions significantly impaired functional recovery as evaluated by white matter sparing and behavioral testing. These data are consistent with a beneficial role for Aβ after SCI. PMID: 24630972 [PubMed – as supplied by publisher] (Source: Brain Research)

See original article here:

Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury.

Leave a Comment

More from category

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]

MS Society Disappointed with Senate Healthcare Bill
MS Society Disappointed with Senate Healthcare Bill

/About-the-Society/News/HealthcareBill-6-22 [Read More]

Type I interferons could have role in natural improvement of RA during pregnancy
Type I interferons could have role in natural improvement of RA during pregnancy

An international US-Danish team of scientists, led by Damini Jawaheer, Ph.D. at the UCSF Benioff Children's Hospital [Read More]

Shared decision-making essential to optimal treatment and quality of life for patients with MS
Shared decision-making essential to optimal treatment and quality of life for patients with MS

One of the cornerstones of multiple sclerosis treatment is shared decision-making between patients and their doctors [Read More]

UC consortium formed to speed up development of new drugs
UC consortium formed to speed up development of new drugs

For 12 years, UCLA researcher Dennis Slamon pursued a groundbreaking approach to treating breast cancer: Attack the [Read More]